Clinical Pharmacokinetics of Metformin

@article{Graham2011ClinicalPO,
  title={Clinical Pharmacokinetics of Metformin},
  author={Garry G Graham and Jeroen Punt and Manit Arora and Richard Osborne Day and Matthew P. Doogue and J K Duong and Timothy J. Furlong and Jerry R. Greenfield and Louise C. Greenup and Carl M J Kirkpatrick and John E. Ray and Peter Timmins and Kenneth Mapson Williams},
  journal={Clinical Pharmacokinetics},
  year={2011},
  volume={50},
  pages={81-98}
}
Metformin is widely used for the treatment of type 2 diabetes mellitus. [...] Key Result The population mean renal clearance (CLR) and apparent total clearance after oral administration (CL/F) of metformin were estimated to be 510 ± 130 mL/min and 1140 ± 330 mL/min, respectively, in healthy subjects and diabetic patients with good renal function.Expand

Paper Mentions

Interventional Clinical Trial
The METHOD study will examine whether adding metformin to standard antibiotic treatment for tuberculosis (TB) in people with HIV is safe and well tolerated. The study will also test if… Expand
ConditionsHIV Coinfection, Pulmonary Tuberculosis, Tuberculosis
InterventionDrug
Interventional Clinical Trial
Melatonin is a hormone that regulates the circadian cycle in addition to having an antioxidant effect. Patients with prediabetes state, has a deregulation of glucose metabolism… Expand
ConditionsPreDiabetes
InterventionDrug
Interventional Clinical Trial
This is a presurgical (proof of principle, window of opportunity) study in patients with surgically resectable thoracic tumors to determine steady-state tissue and plasma… Expand
ConditionsThoracic Neoplasm
InterventionDrug
Interventional Clinical Trial
The aim of the study is to evaluate the effect of nilotinib on the pharmacokinetics and pharmacodynamics of metformin in healthy male adults  
ConditionsHealthy
InterventionDrug
Pharmacokinetics of metformin in the rat: assessment of the effect of hyperlipidemia and evidence for its metabolism to guanylurea.
TLDR
Hyperlipidemia by itself did not affect the pharmacokinetics of metformin, and comparative chromatographic elution times and mass spectra suggested that one of the predominant metabolites was guanylurea. Expand
Effect of plasma membrane monoamine transporter genetic variants on pharmacokinetics of metformin in humans
TLDR
The genetic variation of c.883-144A>G SNP in PMAT significantly affects the renal clearance of metformin in healthy Korean male subjects, and the role of PMAT genetic variations on the pharmacokinetic characteristics of metforms in a Korean population is evaluated. Expand
Mechanism of Metformin: A Tale of Two Sites
TLDR
Surprising results from their clinical trials suggest the primary effect of metformin resides in the human gut, as well as counteracting the cardiovascular complications of type 2 diabetes. Expand
Metformin Sinusoidal Efflux from the Liver Is Consistent with Negligible Biliary Excretion and Absence of Enterohepatic Cycling
TLDR
It is demonstrated that despite similar magnitude of metformin liver and kidney distribution, met formin biliary excretion is negligible due to predominant sinusoidal efflux from the liver. Expand
Population pharmacokinetics and dosing optimization of metformin in Chinese patients with type 2 diabetes mellitus
TLDR
The results of the simulation showed that patients with type 2 diabetes mellitus administered metformin twice a day require higher total daily doses than those with a regimen of 3 times a day at each stage of kidney function, and eGFR had a significant impact on meetformin pharmacokinetics. Expand
Metformin and its gastrointestinal problems: A review
TLDR
It is used clinically in diabetes, polycystic ovary syndrome, and in obese for weight reduction and has cardioprotective effect and its use is recently being studied in cancer and HIV associated metabolic abnormalities. Expand
Population Pharmacokinetics of Metformin in Mexican Patients with Type 2 Diabetes Mellitus
TLDR
In the PPM of metformin in Mexican patients with T2DM here described, the covariates, LBW and CLcr had a significant influence on interindividual variability of V/F and CL/F. Expand
Investigation of possible pharmacokinetic interaction of metformin with sugar replacement sweeteners in rats.
TLDR
Investigation of possible effects of two types of sweeteners; stevia and aspartame on the pharmacokinetic parameters of metformin in rats showed that administration of these two sweeteners did not have high effect on pharmacokinetics of meetformin. Expand
Pharmacokinetic interaction between telithromycin and metformin in diabetes mellitus rats
TLDR
After the oral and intravenous administration of both drugs together, the total area under the plasma concentration–time curve (AUC) of metformin was comparable possibly due to the increased intestinal metabolism of met formin by telithromycin. Expand
Effect of Concomitant Administration of Trospium Chloride Extended Release on the Steady-State Pharmacokinetics of Metformin in Healthy Adults
TLDR
No dosage adjustment is necessary for met formin when coadministered with trospium chloride XR and metformin under steady-state conditions in healthy male and female subjects, and no safety/tolerability issues of concern were observed with coadministration. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 109 REFERENCES
Pharmacokinetics of metformin after intravenous and oral administration to man
TLDR
The kinetics of14C-metformin have been studied in five healthy subjects after oral and intravenous administration, which resulted in a plasma concentration profile of “flip-flop” type for oral metformin. Expand
Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin
TLDR
It is suggested that Oct1 is responsible for the hepatic uptake as well as playing a role in the intestinal uptake of metformin, whereas the renal distribution and excretion are mainly governed by other transport mechanism(s). Expand
Kidney Function and Age Are Both Predictors of Pharmacokinetics of Metformin
TLDR
Both creatinine clearance (CLcr*; corrected for body surface area) and age are predictors of metformin clearance, with the following model best fitting the data: CL/F [or (CL/F)b, CLR, CLR] = α + β·CLCr* + γ · CLcr*·age. Expand
Effect of Cephalexin on the Pharmacokinetics of Metformin in Healthy Human Volunteers
TLDR
It is concluded that cephalexin inhibits the renal tubular secretion of metformin resulting in higher circulating serum concentrations and is responsible for the increase in Cmax and AUC in healthy human volunteers. Expand
Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers
TLDR
The vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet can be administered in the same manner as metformin, and can be recommended to be taken with meals to reduce the gastrointestinal symptoms associated with metformIn. Expand
Disposition of metformin (N,N‐dimethylbiguanide) in man
TLDR
Kinetic parameters ol metformin (N,N‐dimethylbiguanide), an anti‐diabetic reported to be associated with a lower number of episodes of lactic acidosis than phenformin, were determined in volunteers with normal renal function and in patients with different degrees ol renal impairment, to help explain the lower incidence of toxic effects. Expand
Metformin kinetics in healthy subjects and in patients with diabetes mellitus.
TLDR
Plasma metformin concentrations measured throughout the seventh and fourteenth days of continuous 0.5 g twice daily treatment were accurately predicted from single dose data, although a discrepancy between observed and predicted trough levels reflected the existence of a slow elimination phase. Expand
Kinetics of plasma and erythrocyte metformin after acute administration in healthy subjects.
TLDR
Having demonstrated the rapid elimination of metformin from plasma and its slow disappearance from erythrocytes, the present results should contribute to adjustment of met formin dosage to renal function, assessment of drug compliance, and retrospective analysis of the link between meetformin and development of lactic acidosis. Expand
Clinical Pharmacokinetics and Pharmacodynamics of Allopurinol and Oxypurinol
TLDR
Measurement of plasma concentrations of oxypurinol in selected patients, particularly those with renal impairment, may help to decrease the risk of toxicity and improve the hypouricaemic response. Expand
The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects--a double blind placebo-controlled, crossover study.
TLDR
The co-ingestion of 120 mg of EGb 761 and 500 mg of metformin did not significantly affect the pharmacokinetic properties of met formin, and further studies are required to verify this observation. Expand
...
1
2
3
4
5
...